JULY 13, 2016 (SAN ANTONIO, TX) bioAffinity Technologies today announced the renewal of its collaborative agreement with The University of Texas Health Science Center at San Antonio for research and development of novel cancer diagnostic and therapeutic agents using the Company’s porphyrin-based technology platform. This announcement marks the fourth year of collaboration. Leading the University’s […]
JULY 7, 2016 (SAN ANTONIO, TX) bioAffinity Technologies today announced that William Bauta, Ph.D., will join the company in September 2016 as Senior Vice President for Research and Development, Therapeutics. Dr. Bauta will direct the development and commercialization of targeted drugs for the treatment of multiple cancers at bioAffinity’s wholly owned subsidiary, OncoSelect Therapeutics, LLC. “Dr. […]
JUNE 23, 2016 (SAN ANTONIO, TX ) bioAffinity Technologies today announced the formation of OncoSelect Therapeutics, LLC, a subsidiary company that will leverage bioAffinity’s proprietary porphyrin-based diagnostic technology to target a variety of cancers for precision treatment. bioAffinity’s porphyrin-based CyPath® bio-label preferentially binds to cancer cells as compared with non-cancer cells. The CyPath®-labeled cancer cells […]
APRIL 4, 2016 (SAN ANTONIO, TX) bioAffinity Technologies, a privately held cancer diagnostics company, today announced that Vivienne Rebel, M.D., Ph.D., has joined the Company as Executive Vice President of Research and Development (R&D) and Chief Medical and Science Officer. Dr. Rebel’s team will also include David Elzi, Ph.D., as Director of Basic and Applied […]
DECEMBER 14, 2015 (SAN ANTONIO, TX ) bioAffinity Technologies announced the People’s Republic of China awarded a Certificate of Invention Patent for the Company’s proprietary CyPath® assay, a bio-label that preferentially binds to cancer cells and labels them a brilliant crimson red that can be detected and measured by fluorescent imaging. The patent awards protection […]
DECEMBER 10, 2015 SAN ANTONIO–(BUSINESS WIRE)–The porphyrin compound used in bioAffinity Technologies’ proprietary CyPath® Lung is a novel marker for endocytosis, new research shows. Endocytosis is a process that is often disrupted in cancer. The finding will be presented at the 2015 annual meeting of the American Society for Cell Biology (ASCB) on Monday, Dec. […]